Kevan shokat biography of barack

Kevan Shokat

Kevan Michael Shokat (born August 26, )[1] is an American chemical biologist.

See full list on digital.sciencehistory.org That pivot has led to remarkable breakthroughs. Kevan has come a long way since the days when his research was disregarded as unrealistic and unorthodox. They were so far ahead. The Science History Institute recognizes there are materials in our collections that may be offensive or harmful, containing racist, sexist, Eurocentric, ableist, or homophobic language or depictions.

He is a Professor and chair in the Department of Cellular and Molecular Pharmacology at University of California, San Francisco, a professor in the Department of Chemistry at University of California, Berkeley, and an Investigator with the Howard Hughes Medical Institute.

Shokat received his B.A, in chemistry from Reed College in , completing his thesis, "Synthesis of a precursor of PRCPCP, a non-hydrolyzable analog of phosphoribosylpyrophosphate (PRPP)," with Ron McClard, and his Ph.D.

from University of California, Berkeley in , under Peter G. Schultz.

Shokat is one of the leading figures in the field of chemical genetics.[2] He uses methods of bioorganic chemistry to elucidate signal transduction pathways at the single cell and whole organism levels, and is particularly interested in protein kinases, and developing methods to elucidate the particular targets of each kinase, such as the Bump and hole method.

In Shokat published the first covalent inhibitors of KRAS G12C using a tethering screen.[3] Following this strategy many pharma companies have developed KRAS programs leading to phase I/II clinical trials in this space, a landmark for what was once thought to be an undruggable oncogene.

See full list on digital.sciencehistory.org While most researchers focus on modifying the genetic structure of cells, Kevan was more interested in blocking kinase signal paths directly. No other kinases found in either cell line showed strong affinity for the test molecule. Front Matter and Index. I had a pent-up curiosity that got satisfied when I started taking classes here.

  1. ^"Oral history interview with Kevan M. Shokat". Science History Institute Digital Collections. Retrieved
  2. ^"Kevan Shokat at the Michael j. Fox foundation". Retrieved 1 February
  3. ^Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.

    (November ).

    Kevan shokat biography of barack He majored in chemistry and enjoyed lectures offered by Thomas G. Chemists had little insight into the molecular workings of cells, and biologists were not skilled at chemical approaches to the cell. Then I realized if you really understand [cancer], you should be able to make a drug to turn it off. Compared to conventional chemotherapeutic drugs, which mow down healthy and cancerous cells alike in a statistically driven war of attrition, kinase inhibitors attack diseased cells only, leaving healthy cells unscathed.

    "K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions". Nature. (): – BibcodeNaturO. doi/nature PMC&#; PMID&#;

  4. ^"Kevan M. Shokat, Ph.D."
  5. ^"The Protein Society&#;: Protein Society Awards". . Archived at the Wayback Machine
  6. ^Eli Lilly Award in Biological ChemistryArchived at the Wayback Machine, Prizewinners - , retrieved 1/26/
  7. ^Kevan M.

    Shokat, at National Academy of Sciences (), retrieved 1/26/

  8. ^Book of Members –present, Members of the American Academy of Arts & Sciences, , retrieved 1/26/
  9. ^"Ronald Breslow Award for Achievement in Biomimetic Chemistry".
  10. ^"Kraft Prize Symposium".
  11. ^"Frank H.

    Westheimer Prize".

  12. ^"Priming Cancer Cells for Detection by the Immune System". July
  13. ^"Past Recipients".
  14. ^"Kevan Shokat Ph.D.

    See full list on digital.sciencehistory.org These drugs, which have cleared phase I clinical trials setting safe doses and proving human safety , showed significant results in patients, both blocking cancer growth, and, in the case of INK, interrupting metastasis, the devastating spread of cancer cells throughout the body. Next, they crafted a series of special molecules to probe the phosphate binding site of the v-Src kinase present in their mutated strain. Yet despite the accolades he has garnered, he refuses to rest on his laurels, knowing full well that lives depend on the continued progress of his work. His work ethic showed up early at Reed.

    To be Awarded the First SWCRF Breakthrough Science Award".

  15. ^"AACR Announces Recipients of its Scientific Achievement Awards and Lectureships".
  16. ^"NAS Award for Scientific Discovery".
  17. ^"Dr. Kevan Shokat '86 Receives Vollum Award for Cancer Research". 17 February
  18. ^"Sjöberg Laureate brings new hope to people with lung cancer".